drugset / Trial / NCT00706446

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

NCT00706446

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is looking at the effects of certain long-acting bronchodilators on patients with asthma who have specific genetic variations. The investigators are interested in a certain common genetic variation in the receptor for beta-agonists, which is found in as many of one-sixth of the population. There is evidence that patients with asthma who have this variation may not do as well when treated with albuterol on a regular basis. The investigators will be looking at whether patients with this variation have more asthma exacerbations over the course of a year when treated with salmeterol or formoterol, which are long-acting forms of albuterol; and whether these patients have fewer exacerbations when treated with tiotropium, which is a different long-acting bronchodilator that does not act at this receptor. In both groups patients will also be receiving inhaled steroids.

Timeline

Start
2008-06
Primary completion
2010-06
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Formoterol Other / unclassified 12 ug Inhaled
Comparator Salmeterol Other / unclassified 50 ug Inhaled
Subject Tiotropium Other / unclassified 18 ug Inhaled
Background Budesonide Small molecule 90 ug Inhaled
Background Budesonide Small molecule 180 ug Inhaled
Background Fluticasone propionate Other / unclassified 44 ug Inhaled
Background Fluticasone propionate Other / unclassified 100 ug Inhaled
Background Fluticasone propionate Other / unclassified 110 ug Inhaled
Background Fluticasone propionate Other / unclassified 220 ug Inhaled

Indications